WellPrept Patient Education · Cancer Series

Understanding Metastatic Prostate Cancer

A guide for men whose prostate cancer has spread. Treatment has changed a great deal, and this guide covers what is used today.

Version 1.0 · May 2026 Medically reviewed · Next review May 2027

Welcome

Hearing that your prostate cancer has spread is hard, and most men open a browser to look up survival numbers. The figures you find on the first page of Google were collected before 2018 and predate the combinations now used on day one. They will tell you something darker than what your team is offering you.

Treatment for this cancer has been rebuilt in the last ten years. Hormone therapy on its own is rarely the whole first plan. A second pill is now layered in on day one for most men, chemotherapy is added for some, and a radioligand drug (Pluvicto) and PARP inhibitors are waiting for later lines. Average survival on first-line treatment in the hormone-sensitive state now runs past five years for many groups, and a meaningful subset of men do well for considerably longer.

Treatment has side effects, and Chapter 7 and Chapter 8 cover them in detail. Some men live with this disease for many years. Others have a shorter course. The goal is to live as long and as well as possible.

This guide pairs with the Cancer Basics guide, which explains the general words and the workup that go with any cancer. Read that one first if you have not yet.

How to use this guide. Read it once at your own pace. Highlight what fits. Skip what does not. Bring the questions in Chapter 14 to your next visit. You do not have to remember all of this, just where to find it again.

Chapter 01

What metastatic prostate cancer means

Metastatic means the cancer has left the prostate and set up colonies somewhere else in the body. The plan shifts to treatment that travels through the bloodstream.

Where prostate cancer spreads

Roughly 80 to 90 out of 100 men with metastatic prostate cancer have spread to bone. The next most common site is lymph nodes outside the pelvis, followed by the liver and lungs in a smaller group. Other organs are involved less often. The number of spots on the first set of scans can range from a single bone lesion to dozens. In either case the drug choices come from the same group, though the plan changes around the edges: more upfront combination for high-volume disease, sometimes radiation to the prostate itself for low-volume disease.

Three ways men arrive here

  • Found at first diagnosis. A man comes in with bone pain, an elevated PSA, or an unexpected scan finding. The workup shows the cancer is already metastatic. Roughly 8 to 10 out of 100 new prostate cancer diagnoses in the US are metastatic at the start.
  • Found later. A man treated years earlier for an early prostate cancer has a slow rise in PSA, then a scan shows spread. This can happen many years after the first treatment.
  • Found after a slow PSA rise. A man who has been on hormone therapy for a rising PSA develops a spot on a scan for the first time.
8-10%
Of new US prostate cancer diagnoses are already metastatic at the start.
Bone
The most common place prostate cancer spreads. Lymph nodes, liver, and lungs come next.
5+ yrs
Average survival on first-line therapy now runs past five years for many groups.

What changed, and what is true today

Most men walk into the office assuming metastatic prostate cancer means a few months. For the majority of men in 2026 that is wrong by years. With the drug combinations used today, the average man in the hormone-sensitive state goes past five years on first-line therapy, and the men with low-volume disease tend to do better than the average. This is a long illness managed in stages, with the drugs changing as the cancer changes.

Metastatic prostate cancer is usually not curable the way an early prostate cancer can be cured with surgery or radiation. The treatment goal is control: keep the PSA down, keep new spots from forming, and keep you feeling like yourself. Many men get years of stability on the first plan. A smaller group respond briefly. Your team will know which group you are in after the first two sets of labs and scans, usually three to six months in.

!
Older numbers do not fit you

If you searched survival figures before reading this, you likely landed on data from before 2018, when the combinations we use today were not yet standard. Those numbers are darker than what your team is offering you now. Ask your oncologist for current numbers for your specific state (hormone-sensitive or castration-resistant) and your volume (high or low).

Chapter 02

How it is found and confirmed

Before treatment, your team needs a clear picture of where the cancer is and what kind of cells it is made of. This usually takes a set of scans, blood work, and sometimes a fresh biopsy.

The scans

  • Prostate-specific membrane antigen (PSMA) PET/CT. A newer scan that lights up cells carrying the PSMA protein, which sits on most prostate cancer cells. It picks up spread earlier and at lower PSA levels than older scans. This is now the preferred scan at most US cancer centers for staging and for restaging when PSA rises.
  • Bone scan plus CT of the chest, belly, and pelvis. The older standard. Still used at many centers, and still the basis for most treatment trials. Your team may use both kinds of scans in the same workup.
  • MRI. Used when a spot in the spine could be pressing on the spinal cord, or to look closer at a confusing finding.

The tissue

Most prostate cancer that has spread is the same type your team saw at first diagnosis (called adenocarcinoma). Sometimes the team will biopsy a spot of spread to make sure nothing has shifted. A fresh biopsy is also useful when the team needs new tissue for genetic testing on the tumor.

One type of shift to know about is called treatment-emergent neuroendocrine or small-cell prostate cancer. It happens to roughly 15 to 20 out of 100 men whose cancer has been on hormone treatment for years. Signs include a falling or low PSA in the face of clearly growing disease on scans, new spots in the liver, or a quick decline. A biopsy of a growing spot confirms it. The treatment plan changes if this is found.

The labs

Blood work usually includes PSA, testosterone, a bone marker called alkaline phosphatase, LDH, blood counts, and kidney and liver numbers. A bone density scan (called DEXA) is done before you start long-term hormone therapy. Your team also checks heart risk, especially if you have had heart trouble.

i
Ask for a copy of your reports

You are allowed to have copies of your pathology and scan reports. Bring them to your next visit. Mark words you do not know. Your team will go through them with you. These reports help decide which drugs your team can offer you.

Chapter 03

Two states: hormone-sensitive vs castration-resistant

In advanced prostate cancer, the most important question at every visit is which of two states you are in. Your treatment options depend on the answer.

What testosterone has to do with it

Prostate cancer cells feed on a hormone called testosterone. Bringing testosterone down to a very low level (called castrate level, under 50 ng/dL) shrinks most prostate cancers. This is the base of treatment for advanced disease. Lowering testosterone is called androgen deprivation therapy (ADT).

The two states

mCSPC
Hormone-sensitive. The cancer still responds to lowering testosterone. Most men start here. With today's combinations, the response often lasts several years.
mCRPC
Castration-resistant. The cancer grows even with testosterone at castrate level. The drug options change, and tumor genetics start to drive treatment choices.
< 50
Castrate level testosterone in ng/dL. The base of advanced prostate cancer treatment.

You may also hear the shorter terms hormone-sensitive and castration-resistant. Some teams add the letter "m" for metastatic at the front: mCSPC and mCRPC.

How the shift happens

After months or years of low testosterone, the cancer cells adapt. Some make more of the receptor that reads testosterone, so even tiny amounts in the bloodstream are enough to keep them growing. Some begin making their own testosterone inside the tumor. Some find side pathways that bypass the receptor altogether. The newer pill class (abiraterone, enzalutamide, apalutamide, darolutamide) was built around these escape routes and works in this state.

How the team defines the shift

Your team calls it castration-resistant when you are on ADT with castrate testosterone and one of these happens:

  • Three rises in PSA in a row, two weeks apart, with the final value above 2 ng/mL
  • A new or growing spot of cancer in soft tissue or organs on a scan
  • Two or more new bone spots on a bone scan
!
Crossing into the second state

The shift to castration-resistant is part of how this disease moves over time. The first plan stopped working, and your team will switch to a different class of drug. PARP inhibitors, Pluvicto, second-line chemotherapy, and immune therapy all become options here. Ask your team which state you are in at each visit, because the options change once the cancer becomes castration-resistant.

Chapter 04

High-volume vs low-volume disease

In the hormone-sensitive state, the second axis your team looks at is how much cancer is showing on the scans. This sorts men into high-volume and low-volume, and it guides how strong the first treatment combination should be.

The simple version

The split comes from a study called CHAARTED. It uses the older bone scan plus CT to define volume.

VolumeDefinitionWhat it means for treatment
High-volumeCancer in an organ such as the liver or lungs (other organs less often), OR 4 or more bone spots with at least one outside the spine and pelvis.Triplet therapy (ADT + ARSI pill + docetaxel chemo) shows its biggest survival gain here, if you are fit for chemo.
Low-volumeEverything else: spread to lymph nodes only, or limited bone spots that sit only in the spine and pelvis.Doublet therapy (ADT + ARSI pill) is enough for most men. Prostate radiation may be added in de novo cases.

Why your team asks this

Adding chemotherapy on top of hormone therapy and a newer pill is called triplet therapy. Its biggest survival gain shows up in high-volume disease. For low-volume disease, hormone therapy plus a newer pill (called doublet therapy) is enough for most men. Chapter 5 walks through what these names mean.

A caveat about scans

The high-volume and low-volume labels were set using older scans (bone scan and CT). The newer PSMA PET scan picks up more spots. So a man who looks low-volume on the older scans may have extra spots that only show up on PSMA PET. Most US cancer teams still use the older definition to pick the drug combination, with the PSMA PET helping fill in the bigger picture.

De novo vs metachronous

One more split your team will note. Was the cancer spread at first diagnosis (called de novo), or did it come back years after a first treatment (called metachronous)? De novo disease tends to be a bit more aggressive on average. For men with de novo, low-volume disease, adding radiation to the prostate itself on top of drug treatment has been shown to help men live longer. Ask if that fits your case.

i
A fair ask at your next visit

"Am I hormone-sensitive or castration-resistant? If I am hormone-sensitive, is my disease high-volume or low-volume? And is this combo the strongest one I can handle?"

Chapter 05

First-line treatment: doublets and triplets

Hormone therapy alone is no longer the standard for newly diagnosed metastatic prostate cancer. Most men start a combination on day one, and your team picks the combination to fit your case.

The hormone therapy piece (the foundation)

Almost every man starts ADT to lower testosterone. The choices include:

  • Leuprolide or goserelin. Injections every 1, 3, 4, or 6 months. The historical default. Causes a short rise in testosterone in the first week or two; a short course of an antiandrogen pill blocks that rise when needed.
  • Degarelix. A monthly shot that drops testosterone in days, with no flare.
  • Relugolix. A daily pill that drops testosterone within days. In one study, men with prior heart problems had fewer heart events on relugolix than on leuprolide. Many oncologists prefer it for men at higher heart risk.
  • Surgery to remove both testicles. A one-time fix, simple and fully effective. Less common in the US now, since the drug options work well.

The doublet (added to hormone therapy)

For most men with mCSPC (hormone-sensitive disease that has spread), your team adds one of four pills. The group is called androgen receptor pathway inhibitors. All four help men live longer.

  • Abiraterone with a small dose of prednisone. Watch for liver numbers, blood pressure, low potassium, fluid buildup.
  • Enzalutamide. Watch for fatigue, falls, blood pressure, changes in thinking, and rarely a seizure.
  • Apalutamide. Watch for rash, low thyroid, falls.
  • Darolutamide. Of the four, this one has the fewest brain side effects. Watch for fatigue, blood pressure.

The triplet (added in high-volume disease)

For many men with high-volume disease who are fit enough, your team adds six rounds of a chemotherapy called docetaxel on top of hormone therapy and a pill. Two large studies (called ARASENS and PEACE-1) showed extra survival from this triplet in high-volume disease. The triplet has not shown the same gain in low-volume disease.

How your team picks

  • High-volume: often a triplet, if you are fit for chemotherapy. If not, a doublet.
  • Low-volume: a doublet. Sometimes prostate radiation added on top, for men with de novo low-volume disease.
  • Frail or older men: a doublet, sometimes just hormone therapy with the door open to add more later.
  • Past heart trouble: often relugolix as the hormone piece, often darolutamide as the pill.

It is fair to ask your team to walk you through these choices, and to ask why one combination over another.

Chapter 06

When the cancer becomes castration-resistant

For most men, the first plan eventually stops working and your team will call the disease castration-resistant. This opens more drug options, and the order in which you take those drugs starts to matter as much as which ones you choose.

The options in this state

  • Another androgen receptor pathway pill (such as enzalutamide or abiraterone), if you did not get one in the hormone-sensitive state.
  • Docetaxel chemotherapy. Often used for men with cancer that has reached an organ, or that is moving fast.
  • Cabazitaxel chemotherapy. A second type of chemo, used after docetaxel and one pill.
  • Radium-223 (Xofigo). A bone-targeted drug given by IV. For men whose cancer is in bone but not in organs.
  • Lutetium-177 PSMA-617 (Pluvicto). A newer radioligand drug. It binds the PSMA protein on prostate cancer cells and delivers radiation right to the cancer. Six infusions, every six weeks. Survival benefit shown in a study called VISION. A 2025 expansion of the label moved it earlier in the sequence for some men.
  • PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib). These pills work in men whose tumor has a mutation in genes such as BRCA1, BRCA2, or ATM. Sometimes paired with a pill from the androgen receptor pathway family.
  • Pembrolizumab. An immune therapy that works in a small group of men whose tumor has a feature called MSI-high or dMMR. About 3 to 5 out of 100 men with metastatic prostate cancer fit.
  • Sipuleucel-T (Provenge). An IV that uses your own immune cells. Approved for men with few or no symptoms. The survival gain is modest.
  • A clinical trial. A fair option at any line, and a strong one after a second-line drug stops working.

How the team picks the order

No one sequence is right for every man. The choice depends on what you have taken, what your tumor's gene tests show, your other health, where the cancer is, and your goals.

  • Your tumor may have a BRCA1, BRCA2, or related gene change. If so, your team will look hard at a PARP inhibitor early.
  • If your tumor is MSI-high, pembrolizumab is a strong option. Do not miss it.
  • If the cancer is only in bone and is causing pain, radium-223 is an option.
  • Lutetium-177 PSMA-617 (Pluvicto) helps men live longer in a specific setting. It is for men who have had at least one pill and one chemo, and whose PSMA PET shows the cancer is PSMA-positive.
i
A second opinion is normal here

When you are picking the order of drugs in mCRPC, a second opinion is standard practice. A high-volume cancer center is a good place to get one. That can be a regional academic center or an NCI-designated cancer center. Some clinical trials only open at those sites. A fresh set of eyes on the plan is part of how this disease gets managed well in 2026, and most community oncologists welcome it.

Chapter 07

Side effects, by drug class

This table lays out the side-effect picture for every drug class your team is likely to use. Numbers are rough, and your own experience will vary. Tell your team early about anything new.

Drug classCommon side effectsSerious to know about
ADT (any kind)Hot flashes (50 to 80 out of 100), loss of sex drive, erection trouble, fatigue, weight gain, muscle lossBone loss and fracture, higher diabetes risk, higher heart risk, mood changes, thinking changes
Abiraterone + prednisoneHigh blood pressure, low potassium, fluid swelling, fatigueLiver inflammation (labs are watched), adrenal effects from prednisone
EnzalutamideFatigue, falls, high blood pressure, hot flashes, thinking changesSeizure (rare, under 1 out of 100); avoid if you have a seizure history when other options exist
ApalutamideRash (sometimes severe), fatigue, low thyroid, fallsSevere skin reactions, rare seizure
DarolutamideFatigue, high blood pressure, rashLowest brain-side-effect rate of the four. Often picked when thinking or fall worries matter most
DocetaxelFatigue, hair loss, low blood counts, numbness or tingling, nail changes, taste changeFever with low white count is an ER trip. Severe lasting numbness
CabazitaxelLow white count, diarrhea, fatigue, less numbness than docetaxelFever with low white count. White-blood-cell shots are often given
Radium-223Fatigue, nausea, loose stools, low blood counts, brief flare of bone pain in first cycleHigher fracture risk if combined with abiraterone (your team avoids that pairing). Marrow effects
Lutetium-177 PSMA-617Dry mouth, fatigue, nausea, low red and platelet countsBone marrow effects, rare kidney effects, salivary gland effects
PARP inhibitorsAnemia, fatigue, nausea, low blood countsRare blood disorders (under 1 out of 100), rare lung inflammation
PembrolizumabFatigue, rash, itching, loose stoolsImmune system attacks normal organs (thyroid, lung, liver, gut, skin, pituitary). Can be severe and lasting
Sipuleucel-TChills, fever, fatigue after the infusionUsually well tolerated
Zoledronic acid / denosumabFatigue, flu-like feeling after dose, joint pain, low calciumJawbone problem (osteonecrosis of the jaw). Dental visit before starting. Do not stop denosumab without a transition plan

A fuller side-effect conversation for hormone therapy specifically is in Chapter 8. Bone-modifying drugs are covered in Chapter 9. Same-day call versus ER signs are in Chapter 12.

Chapter 08

Living well on long-term hormone therapy

Most men with metastatic prostate cancer are on hormone therapy for the rest of their lives. The side effects build slowly, and most of them can be managed.

Hot flashes

Between 50 and 80 out of 100 men on ADT get hot flashes. They range from mild and once in a while to drenching and disruptive. A cooler room, layered clothing, and watching for triggers (alcohol, hot drinks, spicy food) help. A low dose of a medication called venlafaxine often works well; gabapentin and a low dose of paroxetine or oxybutynin are other options. Acupuncture has modest evidence.

Sex and intimacy

Loss of sex drive on ADT is near-universal within the first three to six months. Erections usually do not come back on hormone therapy, and the pills you may have used before (sildenafil, tadalafil) work poorly without testosterone in the system. A vacuum erection device, penile injections (alprostadil or trimix), and a penile prosthesis are the options that still work in this setting. Many couples find that the conversation with a partner about what intimacy looks like now matters more than any device. If you want help with that conversation, a sex therapist who works with cancer patients is often a faster fix than a urologist.

Fatigue and muscle loss

The single best fix for hormone-therapy fatigue is resistance exercise. Two or three short sessions a week, with weights or bands, works better than almost any pill for fatigue, muscle loss, and quality of life. Walking, biking, and swimming all help too. A coached program at the start builds a better habit.

Bones

Hormone therapy accelerates bone loss, even before any cancer reaches the bones. A baseline DEXA scan at the start, repeat every 1 to 2 years. Calcium 1000 to 1200 mg per day and vitamin D 800 to 1000 IU per day are standard. The bone-modifying drugs in Chapter 9 cover both bone-spot risk and bone loss.

Heart and metabolism

Long-term hormone therapy raises several health risks. These include weight gain (often around the belly), higher blood sugar, higher cholesterol, higher blood pressure, and new type 2 diabetes. Work with your primary care doctor on these. For men who have had heart trouble, relugolix may be the better hormone choice.

Mood, sleep, and thinking

Low mood, anxiety, and complaints about word-finding or focus show up in roughly one in three men on long-term ADT and tend to be under-reported in the office. They are treatable. An SSRI, two or three sessions with a therapist, and good sleep hygiene cover most of the ground. If memory or concentration is the bigger complaint, darolutamide has the fewest brain side effects of the four newer pills. Ask your oncologist whether a switch makes sense.

Body changes

Thinning of body hair, breast tenderness, and shrinkage of the testicles are common within the first year. Some men notice a small amount of penile shortening. Breast tenderness that is bothersome can often be eased. One option is a single low-dose radiation treatment to the breast bud before you start an antiandrogen pill. A short course of tamoxifen is another. Talking about these changes with your partner ahead of time blunts the surprise.

+
Fertility, if it applies

Younger men with metastatic prostate cancer who may want children should ask about sperm banking before starting hormone therapy. The window is narrow.

Chapter 09

Bone health, pain, and emergencies

Bone is where prostate cancer most often spreads. The risks are pain, fracture from a small injury, and a rare but serious situation where a bone in the spine puts pressure on the spinal cord. These risks can be lowered. Some need same-day action.

Bone-modifying drugs

Two drugs lower the chance of fracture and bone pain crises in men with bone spots:

  • Zoledronic acid. Given by IV, usually every four weeks (some teams use every twelve weeks). Watch for kidney effects and rare jawbone problems.
  • Denosumab (Xgeva). Given as an injection under the skin, usually every four weeks. Slightly more effective than zoledronic acid in some studies. No kidney dose change needed. Watch for low calcium. Do not stop suddenly without a transition plan; stopping can cause rebound spine fractures.

Both drugs can rarely cause a jawbone problem called osteonecrosis of the jaw. Get a dental check before the first dose. Treat any active dental problem first. Tell your dentist you are on one of these drugs.

Pain from a bone spot

A short course of focused radiation (most often a single 8 Gy dose, sometimes 5 to 10 fractions for larger spots) gives strong pain relief within four weeks for roughly 7 out of 10 treated spots. Tell your team about a new painful bone spot the same week it appears. Pain medications are part of the plan. Opioid-induced constipation derails most pain plans, so a stool softener and a stimulant laxative should start the same day the opioid does. The palliative care team in Chapter 11 is a partner on all of this.

Spinal cord pressure is an emergency

!
Spinal cord pressure

New severe back pain with leg weakness, trouble walking, numbness, or new bowel or bladder changes can mean a tumor is pressing on your spinal cord. This is treatable, but only if it is caught quickly. Call your team the same day, or go to the ER. Steroids start immediately. Urgent MRI and a call to neurosurgery and radiation come next.

Fractures and large painful spots

A bone with a large hole, or a bone that has already broken from a small fall, may need orthopedic surgery (a metal rod or plate) and then radiation. A urinary block from the prostate, or a blocked tube from the kidney (called hydronephrosis), may need a stent or catheter. Your team sees all of these often.

Chapter 10

Genetics and your family

Germline and tumor genetic testing are now standard for every man with metastatic prostate cancer. The results change your own treatment options (BRCA mutations open up PARP inhibitors, MSI-high tumors open up pembrolizumab) and they carry information for your sons, daughters, brothers, and sisters. The conversation with family can wait until you are ready.

Two kinds of tests

  • Germline testing. A blood or saliva test. It looks for inherited gene changes that you were born with. These are the ones that matter for your family. Recommended for every man with metastatic prostate cancer, no matter your family history.
  • Tumor (somatic) testing. Done on tumor tissue, or on a special blood test that pulls cancer DNA from the bloodstream. It looks for gene changes the cancer picked up over time. Some of these unlock specific drugs.

About half of BRCA2 mutations found on tumor testing are also inherited. Confirming with germline testing matters for the rest of your family.

Genes that matter most

  • BRCA2. The most common and most important. Linked to more aggressive prostate cancer. Opens the door to PARP inhibitors. Raises risk of breast cancer (in women and men), ovarian, and pancreatic cancer in family members.
  • BRCA1. Less common in prostate cancer. The same things matter when it shows up.
  • ATM, CHEK2, PALB2, and others. A larger family of genes called HRR genes. Some respond to PARP inhibitors.
  • Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM). Raise risk of colon, uterine, urinary tract, and other cancers. A tumor that is MSI-high should trigger Lynch evaluation.

What it means for family

An inherited gene change has a 50 out of 100 chance of being passed to each child, brother, or sister. A genetic counselor can help your relatives think about their own testing on their own time. For BRCA2 specifically:

  • Daughters and sisters may need to start breast and ovarian screening earlier.
  • Sons and brothers may need earlier prostate screening, often starting at age 40.

Telling your family can happen on your timeline, with no rush. A genetic counselor can help with the words.

+
A note on insurance

A federal law called GINA blocks health insurance and employers from using your genetic test results against you. It does not cover life, disability, or long-term care insurance. Some men get those policies in place before testing. A genetic counselor or financial advisor can walk you through this.

Chapter 11

Palliative care, money, and dignity

Quality of life is part of the treatment plan. So is the practical side of a long illness: money, work, family talks, and what end-of-life care looks like when the time comes. These topics belong in the conversation early.

Palliative care versus hospice

This is the most common point of confusion in cancer care. Palliative care is a specialty team that manages pain, nausea, fatigue, sleep, mood, and family conversations. It runs alongside your cancer treatment from day one and has nothing to do with stopping treatment. Studies in lung and pancreatic cancer have shown that patients who saw palliative care within eight weeks of diagnosis had better quality of life scores and, in one trial, lived a few months longer than the group who got standard care alone. Ask your oncologist for a referral at your next visit. Most cancer centers have a palliative care team on staff.

What hospice is

Hospice is a different program. It is comfort-focused care for people who have stopped treatment aimed at controlling the cancer. Hospice does not mean the end is within days. The Medicare hospice benefit covers six months at a time, and roughly half of patients on hospice live longer than the median predicted at sign-up. The conversation usually starts when scans show the cancer is moving despite two or three lines of treatment, when you are spending more days in bed than out, or when the side effects are costing you more than the drugs are buying. Your team will raise it when the time fits. You can raise it earlier.

Money

The newer pills (abiraterone, enzalutamide, apalutamide, darolutamide) have list prices in the range of $10,000 to $15,000 a month before insurance. Pluvicto runs higher per infusion. Most cancer centers have a financial counselor or oncology social worker on staff who can pull co-pay foundation grants, manufacturer assistance programs, and Medicare extra-help paperwork together in one visit. Ask for that referral at the start, not after the first bill arrives. If a co-pay is forcing you to skip doses or stretch a prescription, tell your oncologist; that information often changes the plan.

Work and family leave

The Family and Medical Leave Act protects 12 weeks of unpaid, job-protected leave per year for serious illness at employers with 50 or more workers. Short-term and long-term disability insurance policies vary widely on what they cover and how long benefits last. Sit down with your social worker and pull your own policy documents before guessing. Plenty of men keep working through long stretches of treatment with schedule adjustments, work-from-home days, and lighter travel during chemotherapy cycles.

Mood, isolation, and identity

Long treatment changes how a man relates to his body, his work, and the people closest to him. Some men talk about it openly with a partner or a friend. Many do not, and the distance from people they love builds over months. Low mood, broken sleep, and a sense of being on the sidelines of your own life are common and treatable. A short course of an SSRI, a few sessions with a counselor, or a peer-support group through the Prostate Cancer Foundation can help within weeks.

The long arc

For most men diagnosed in 2026, this is a long illness managed in stages. The drugs change over the years, and so do the priorities. Early on, the focus is hitting the cancer hard with combination therapy. Later, the focus moves to keeping side effects manageable and choosing the order of next-line drugs. Across all of it, treatment aims at both how long you live and how well you live during those years, including how you feel at work, at home with family, and on an ordinary weekend.

Treatment for metastatic prostate cancer aims at both how long you live and how well you live, with the balance shifting from aggressive combination therapy early on to managing side effects and sequencing next-line drugs later.
Chapter 12

Surveillance and the long arc

Treatment in metastatic prostate cancer runs in lines that last months or years. Each line is watched with PSA, scans, and how you feel. This chapter covers what to expect and when to call your team.

How your team watches the cancer

  • PSA every 1 to 3 months during treatment. A 50 percent or greater drop from where you started is a common signal of response.
  • Scans every 3 to 6 months on first-line treatment, sometimes more often if the picture is unclear. PSMA PET where available, with conventional CT and bone scan still common.
  • Blood work to watch each drug. Liver and potassium numbers for abiraterone, blood counts for chemotherapy and PARP inhibitors, thyroid for apalutamide, and so on.
  • How you are doing at every visit: pain, energy, weight, mood, side effects.

A note on the flare phenomenon

In the first three months on a new treatment, a bone scan can light up more than the baseline scan even though the cancer is actually responding. This is called the flare phenomenon and reflects bone healing around the cancer spots. The way your team sorts it out is to repeat the scan 8 to 12 weeks later. If the spots are fading and the PSA is dropping, the first scan was a flare. If the spots are growing and the PSA is rising, the cancer is actually progressing. One scan in isolation rarely gives the answer.

Same-day call versus ER

!
Call your team the same day

New bone pain that does not let up. Fever within 14 days of chemotherapy. A new severe headache. Loose stools many times a day, especially on chemotherapy or pembrolizumab. New shortness of breath. A new cough that is not going away. A spreading rash. Inability to pass urine.

!
Go to the ER

Severe back pain with leg weakness, numbness, or new bladder or bowel changes (possible spinal cord pressure). A high fever with shaking chills. Chest pain. Severe trouble breathing. A sudden swollen, painful leg. A bad headache with vomiting. A seizure. Any change in how clearly you can think.

If a treatment stops working

Your team uses the word progression when the cancer is growing while on treatment. The next step is rarely the end of the road. It usually means switching to the next line. Ask: "What are my options now, and what is your top recommendation?"

i
Scanxiety

Patients on this kind of surveillance often have a name for the week before each scan: scanxiety. A few practical things help. Schedule the scan early in the week so you do not lose a weekend to the wait. Ask your team to book the follow-up call within 48 hours of the result, not a week out. If the anxiety is breaking your sleep or pulling you out of work, two or three sessions with a therapist who works with cancer patients usually helps.

Chapter 13

Survival numbers

Most men look up survival numbers at some point. This chapter walks through how to read them so they help you rather than mislead you.

The big shift

For many years, the average survival for metastatic prostate cancer landed around 2 to 3 years. On modern doublet and triplet combinations, the average in the hormone-sensitive state now runs past 5 years, and longer in low-volume disease. The follow-up on the newest trials is still maturing, so the true numbers may be better than what is currently published. A man diagnosed today sits on a different curve than a man diagnosed in 2010.

Six things to keep in mind

  • Numbers describe a group. Your case has its own state, volume, biology, response, and pace. The group number is only a starting point.
  • Old numbers leak into search results. Many figures online are from before today's combinations were standard.
  • Ask for numbers that fit your state and volume. Low-volume hormone-sensitive disease starts in one place. High-volume castration-resistant disease starts in a very different one.
  • Median is the middle. Half of men live longer. Some live a lot longer.
  • Long tails exist. A meaningful number of men with metastatic prostate cancer live well past their median, especially with deep responses on first-line therapy.
  • Your own response matters most. How your PSA and scans look after the first three to six months tells your team more than any group number.
Statistics describe a population. They do not predict your outcome. Your team can put any number you find next to your own case.

What durable response means

On modern combinations, a meaningful subset of men drive the PSA down below 0.2 ng/mL and hold there for several years. The men who reach an undetectable PSA within six months of starting treatment tend to do best over the long run. Your team usually has a clear read on which group you are landing in by the time the second set of scans comes back, around month six.

If you do not respond

Some men respond briefly, or barely at all. If you are in that group, the next move is usually to switch drug classes rather than push the same one harder. Tumor genetic testing, if it has not been done yet, often opens an option that was not available at the start, especially a PARP inhibitor in BRCA-mutated disease or pembrolizumab in MSI-high disease. Clinical trials are open at every line. Raise the topic with your team early so the next plan is ready before the current one fails.

Chapter 14

Questions to ask your team

Bring this page to your next visit. It is easy to forget the questions you wanted to ask once you are in the room.

About my cancer

  • Am I hormone-sensitive or castration-resistant right now?
  • If I am hormone-sensitive, am I high-volume or low-volume by the CHAARTED rule?
  • Has my case been talked through at a tumor board?
  • Have I had germline and tumor genetic testing? What did they show?

About the first plan

  • Which combination are you recommending, and why this one?
  • Am I fit for a triplet, or is a doublet the right call for me?
  • Should radiation to the prostate be part of my plan?
  • Are there clinical trials that fit me right now?

About side effects and life

  • What side effects should I watch for, and which need a same-day call?
  • What can I do for hot flashes, fatigue, and bone health?
  • What is the plan for sex and intimacy on hormone therapy?
  • Can I see a palliative care team alongside my main treatment?

About family and money

  • What does my genetic testing mean for my children and siblings?
  • Is there a nurse navigator or social worker I can meet?
  • What help is there for the cost of these drugs?

About the path ahead

  • What does it look like if this plan works? If it does not?
  • When would we know it is time to switch lines?
  • What is your honest sense of what is realistic for me?
  • When should we talk about advance directives and end-of-life planning?
Chapter 15

Words to know

General cancer words live in the Cancer Basics guide. These are the ones used most in metastatic prostate cancer care.

Metastatic prostate cancer
Prostate cancer that has spread to far parts of the body, most often bone.
mCSPC (hormone-sensitive)
Metastatic disease that still responds to lowering testosterone.
mCRPC (castration-resistant)
Metastatic disease that grows even with castrate testosterone (under 50 ng/dL).
De novo metastatic
Cancer that was metastatic at first diagnosis.
Metachronous metastatic
Spread that shows up years after treatment for an early prostate cancer.
High-volume / low-volume (CHAARTED)
High-volume = cancer in liver or lung, or 4+ bone spots with one outside spine and pelvis. Low-volume = everything else.
ADT
Androgen deprivation therapy. Lowers testosterone.
LHRH agonist / antagonist
Classes of hormone therapy: leuprolide, goserelin (agonist); degarelix, relugolix (antagonist).
Androgen receptor pathway inhibitor
A class of pills: abiraterone, enzalutamide, apalutamide, darolutamide.
Doublet therapy
ADT plus an androgen receptor pathway pill.
Triplet therapy
ADT plus an androgen receptor pathway pill plus docetaxel chemotherapy.
PSMA
A protein on most prostate cancer cells. The target for PSMA PET scans and for Pluvicto.
PSMA PET/CT
A scan that lights up cells carrying PSMA. Newer and more sensitive than older scans.
Lutetium-177 PSMA-617 (Pluvicto)
A radioligand drug that binds PSMA and delivers radiation to cancer cells.
Radium-223 (Xofigo)
A radioactive infusion that targets bone spots in men without organ spread.
PARP inhibitor
A pill class (olaparib, rucaparib, niraparib, talazoparib) that works in tumors with BRCA1, BRCA2, or related gene mutations.
HRR genes
A family of repair genes that includes BRCA1, BRCA2, ATM, CHEK2, PALB2.
MSI-high / dMMR
A tumor feature that predicts response to pembrolizumab.
Pembrolizumab
An immune therapy used in MSI-high tumors.
Sipuleucel-T (Provenge)
An immune-style infusion for men with few or no symptoms.
Docetaxel / cabazitaxel
Chemotherapies used in metastatic prostate cancer.
Skeletal-related event
A fracture, spinal cord pressure, surgery to bone, or radiation to bone.
Zoledronic acid / denosumab
Bone-modifying drugs that lower fracture and pain risk in men with bone spots.
Osteonecrosis of the jaw
A rare jawbone problem from bone-modifying drugs. Dental check before starting.
Spinal cord pressure
An emergency from a tumor pressing on the spinal cord. Same-day call or ER.
Castrate testosterone
A testosterone level under 50 ng/dL.
PSA response
A 50 percent or greater drop in PSA from where you started.
Flare phenomenon
An early scan that looks worse but reflects healing bone, not progression.
Treatment-emergent neuroendocrine
An aggressive shift in cell type after long hormone-pathway treatment. Roughly 15 to 20 out of 100 mCRPC.
Palliative care
Care for symptoms and quality of life alongside cancer treatment. Not hospice.
Hospice
Comfort-focused care when treatment for control is no longer being pursued.
Progression
The cancer growing while on treatment.
Sources

Sources and further reading

This guide draws on current society guidelines and the major trials behind today's standard of care. The list below points to where you can read more.

  1. NCCN Prostate Cancer Guidelines. nccn.org
  2. NCCN Patient Guidelines: Prostate Cancer (Advanced). nccn.org/patients
  3. EAU Prostate Cancer Guidelines. uroweb.org
  4. CHAARTED (high-volume vs low-volume). nejm.org
  5. LATITUDE (abiraterone in mCSPC). nejm.org
  6. TITAN (apalutamide in mCSPC). nejm.org
  7. ENZAMET (enzalutamide in mCSPC). nejm.org
  8. ARASENS (darolutamide triplet). nejm.org
  9. PEACE-1 (abiraterone triplet). thelancet.com
  10. STAMPEDE arm H (prostate radiation in low-volume mCSPC). thelancet.com
  11. HERO (relugolix and cardiovascular events). nejm.org
  12. VISION (Lutetium-177 PSMA-617 in mCRPC). nejm.org
  13. PROfound (olaparib in HRR-mutated mCRPC). nejm.org
  14. CARD (cabazitaxel after docetaxel and one ARSI). nejm.org
  15. ALSYMPCA (radium-223 in bone-predominant mCRPC). nejm.org
  16. ERA 223 (radium-223 + abiraterone fracture risk). thelancet.com
  17. Prostate Cancer Foundation patient resources. pcf.org
  18. NCI: Prostate Cancer Treatment. cancer.gov
  19. Get Palliative Care. getpalliativecare.org
  20. National Society of Genetic Counselors. nsgc.org
  21. ClinicalTrials.gov. clinicaltrials.gov

About this guide. Work through your own situation with your care team. The numbers, words, and choices in this guide fit each man differently, and your oncologist has details on your case that no general guide can carry. Use this to ask better questions at your next visit.

Playing audio...